A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020 Delayed Release Capsules in Healthy Subjects
Latest Information Update: 27 Mar 2023
At a glance
- Drugs Alkaline phosphatase (Primary)
- Indications Coeliac disease; Inflammatory bowel diseases; Metabolic syndrome; Non-alcoholic fatty liver disease; Radiation injuries
- Focus Pharmacokinetics
- Sponsors Synthetic Biologics; Theriva Biologics
- 13 Oct 2022 According to Theriva Biologics media release, Synthetic Biologics changed it's name to Theriva Biologics
- 10 May 2022 Results published in Synthetic Biologics Media Release
- 19 Apr 2022 Status changed from recruiting to completed.